These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16828196)

  • 21. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
    Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
    Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    Jänne PA; Simon GR; Langer CJ; Taub RN; Dowlati A; Fidias P; Monberg M; Obasaju C; Kindler H
    J Clin Oncol; 2008 Mar; 26(9):1465-71. PubMed ID: 18349397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
    Tanida S; Kataoka H; Kubota E; Mori Y; Sasaki M; Ogasawara N; Wada T; Mizoshita T; Shimura T; Murakami K; Mizushima T; Hirata Y; Okamoto Y; Mabuchi M; Ebi M; Tanaka M; Kamiya T; Takahashi S; Joh T
    Int J Clin Oncol; 2009 Jun; 14(3):266-9. PubMed ID: 19593622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
    Ikehara M; Oshita F; Suzuki R; Saitoh H; Yamada K; Noda K
    J Exp Ther Oncol; 2004 Apr; 4(1):79-83. PubMed ID: 15255294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
    Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
    Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST; Park JY; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    Jpn J Clin Oncol; 2010 Nov; 40(11):1031-6. PubMed ID: 20534685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
    Lee J; Kim TY; Lee MA; Ahn MJ; Kim HK; Lim HY; Lee NS; Park BJ; Kim JS;
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):47-52. PubMed ID: 17364190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
    Maruyama R; Shoji F; Okamoto T; Miyamoto T; Miyake T; Nakamura T; Ikeda J; Aoki Y; Wataya H; Asoh H; Ichinose Y
    Jpn J Clin Oncol; 2005 Aug; 35(8):433-8. PubMed ID: 16006571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
    Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
    Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
    de Gooijer CJ; van der Noort V; Stigt JA; Baas P; Biesma B; Cornelissen R; van Walree N; van Heemst RC; Soud MY; Groen HJM; den Brekel AJS; Buikhuisen WA; Bootsma GP; Dammeijer F; van Tinteren H; Lalezari F; Aerts JG; Burgers JA;
    Lancet Respir Med; 2021 Jun; 9(6):585-592. PubMed ID: 33515500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
    Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
    J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.
    Abratt RP; Bezwoda WR; Goedhals L; Hacking DJ
    J Clin Oncol; 1997 Feb; 15(2):744-9. PubMed ID: 9053500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.